Precision Medicine in Hormone Receptor-Positive Breast Cancer

Frontiers in Oncology

Azadeh Nasrazadani¹  Roby A. Thomas¹  Adrian V. Lee²  Steffi Oesterreich² 

[1] Department of Medicine, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA, United States;Women’s Cancer Research Center, Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Magee Womens Research Institute, Pittsburgh, PA, United States;

关键词: hormone receptor-positive breast cancer;    personalized medicine;    liquid biopsy;    circulating tumor DNA;    circulating tumor cells;   

DOI  :  10.3389/fonc.2018.00144

来源: DOAJ

【 摘 要 】

In recent decades, breast cancer has become largely manageable due to successes with hormone receptor targeting. Hormone receptor-positive tumors have favorable outcomes in comparison to estrogen receptor (ESR1, ER)/progesterone receptor-negative tumors given the targetable nature of these tumors, as well as their inherently less aggressive character. Nonetheless, treatment resistance is frequently encountered due to a variety of mechanisms, including ESR1 mutations and loss of ER expression. A new era of precision medicine utilizes a range of methodologies to allow real-time analysis of individual genomic signatures in metastases and liquid biopsies with the goal of finding clinically actionable targets. Preliminary studies have shown improved progression-free survival and overall survival with implementation of this information for clinical decision making. In this review, we will discuss the opportunities and challenges in integrating precision medicine through next-generation genomic sequencing into the management of breast cancer.

【 授权许可】

Unknown